Using aerosolized vitamin A to help prevent lung injury in premature infants
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
This study is testing a gentle way to give preterm babies a special vitamin A mist to help prevent lung problems and vitamin A deficiency, so they can avoid painful shots and get the nutrients they need more easily.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advent Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Lumberville, United States) |
| Project ID | NIH-11060999 on NIH RePORTER |
What this research studies
This research focuses on developing a non-invasive method to deliver aerosolized vitamin A to preterm infants to prevent vitamin A deficiency and bronchopulmonary dysplasia (BPD), a serious lung condition. The approach involves creating a water-soluble formulation of vitamin A that can be inhaled, avoiding the need for painful injections and improving absorption compared to oral forms. The study builds on previous successful animal model data, demonstrating that this method can effectively mitigate lung damage caused by oxygen exposure in premature infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants, particularly those at risk for vitamin A deficiency and bronchopulmonary dysplasia.
Not a fit: Patients who are not preterm infants or those who do not have vitamin A deficiency or bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of bronchopulmonary dysplasia in preterm infants, improving their lung health and overall outcomes.
How similar studies have performed: Previous studies have shown promising results with similar aerosolized delivery methods for vitamin A in animal models, indicating potential for success in human applications.
Where this research is happening
Lumberville, United States
- Advent Therapeutics, INC. — Lumberville, United States (Active)
Researchers
- Principal investigator: Gelfand, Craig — Advent Therapeutics, INC.
- Study coordinator: Gelfand, Craig
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.